Tracking adverse drug reactions and medication errors in the Central Chronic Medicine Dispensing and Distribution (CCMDD) programme in South Africa.

IF 1.6 4区医学 Q4 INFECTIOUS DISEASES Southern African Journal of Hiv Medicine Pub Date : 2022-05-19 eCollection Date: 2022-01-01 DOI:10.4102/sajhivmed.v23i1.1366

Kennedy Otwombe, Maggie Munsamy, Mukesh Dheda, Nishana Ramdas, Corlee Herbst, Merlin Pillay, Tanya van Tonder, Celicia Serenata, Samanta Lalla-Edward

{"title":"Tracking adverse drug reactions and medication errors in the Central Chronic Medicine Dispensing and Distribution (CCMDD) programme in South Africa.","authors":"Kennedy Otwombe, Maggie Munsamy, Mukesh Dheda, Nishana Ramdas, Corlee Herbst, Merlin Pillay, Tanya van Tonder, Celicia Serenata, Samanta Lalla-Edward","doi":"10.4102/sajhivmed.v23i1.1366","DOIUrl":null,"url":null,"abstract":"Background: The South African Central Chronic Medicine Dispensing and Distribution (CCMDD) programme is a National Health Insurance (NHI) initiative that improves access to medicine for patients.Objectives: To describe the frequency of adverse drug reactions (ADRs) and medication errors reported in stable patients living with HIV.Method: This descriptive cross-sectional survey was conducted from August 2020 to October 2020, targeting tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) and tenofovir disoproxil fumarate/emtricitabine/efavirenz (TEE) patients. The distribution of ADRs and medication errors is presented.Results: Of 9621 patients, 30.8% (n = 2967) were interviewed, 40.2% (n = 1192) on TLD and 59.8% (n = 1775) on TEE regimens. The majority were women (TLD: 55.8%, n = 665; TEE: 75.4%, n = 1338); 15% (179/1192) reported ADRs on TLD. Medication errors were low on TLD (1.6%, n = 19) and TEE (1.2%, n = 22). Receipt of incorrect medication (eight each in TLD and TEE) and associated hospitalisations (one vs two, respectively) were low. Common TLD-associated ADRs were weight gain (47.5%, n = 85), headaches (44.7%, n = 80), insomnia (39.7%, n = 71), restlessness (36.9%, n = 66), dizziness (29.6%, n = 53), brain fog (27.9%, n = 50), nervousness (27.4%, n = 49), rash on the skin (24.6%, n = 44) and poor concentration (21.2%, n = 38).Conclusion: About one in seven patients reported ADRs under TLD. Medication errors were low, possibly due to effective quality control measures and stable patients being on the programme. Knowing the frequency of ADRs and medication errors is critical for enhancing the CCMDD programme.","PeriodicalId":49489,"journal":{"name":"Southern African Journal of Hiv Medicine","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210172/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southern African Journal of Hiv Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajhivmed.v23i1.1366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 1

Abstract

Background: The South African Central Chronic Medicine Dispensing and Distribution (CCMDD) programme is a National Health Insurance (NHI) initiative that improves access to medicine for patients.

Objectives: To describe the frequency of adverse drug reactions (ADRs) and medication errors reported in stable patients living with HIV.

Method: This descriptive cross-sectional survey was conducted from August 2020 to October 2020, targeting tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) and tenofovir disoproxil fumarate/emtricitabine/efavirenz (TEE) patients. The distribution of ADRs and medication errors is presented.

Results: Of 9621 patients, 30.8% (n = 2967) were interviewed, 40.2% (n = 1192) on TLD and 59.8% (n = 1775) on TEE regimens. The majority were women (TLD: 55.8%, n = 665; TEE: 75.4%, n = 1338); 15% (179/1192) reported ADRs on TLD. Medication errors were low on TLD (1.6%, n = 19) and TEE (1.2%, n = 22). Receipt of incorrect medication (eight each in TLD and TEE) and associated hospitalisations (one vs two, respectively) were low. Common TLD-associated ADRs were weight gain (47.5%, n = 85), headaches (44.7%, n = 80), insomnia (39.7%, n = 71), restlessness (36.9%, n = 66), dizziness (29.6%, n = 53), brain fog (27.9%, n = 50), nervousness (27.4%, n = 49), rash on the skin (24.6%, n = 44) and poor concentration (21.2%, n = 38).

Conclusion: About one in seven patients reported ADRs under TLD. Medication errors were low, possibly due to effective quality control measures and stable patients being on the programme. Knowing the frequency of ADRs and medication errors is critical for enhancing the CCMDD programme.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

跟踪南非中央慢性药物调剂和分配(CCMDD)规划中的药物不良反应和用药错误。

背景:南非中央慢性药物配药和分配(CCMDD)计划是一项国民健康保险(NHI)倡议，旨在改善患者获得药物的机会。目的:描述稳定期HIV感染者报告的药物不良反应(adr)和用药错误的频率。方法:该描述性横断调查于2020年8月至2020年10月进行，针对富马酸替诺福韦二氧吡酯/拉米夫定/多替重韦(TLD)和富马酸替诺福韦二氧吡酯/恩曲他滨/依非韦伦(TEE)患者。介绍了药品不良反应和用药错误的分布情况。结果:9621例患者中，30.8% (n = 2967)接受访谈，40.2% (n = 1192)接受TLD治疗，59.8% (n = 1775)接受TEE治疗。多数为女性(TLD: 55.8%， n = 665;TEE: 75.4%， n = 1338);15%(179/1192)报告了TLD的adr。TLD组(1.6%，n = 19)和TEE组(1.2%，n = 22)用药错误发生率较低。接收不正确药物(TLD和TEE各8例)和相关住院(分别为1例对2例)的情况很低。常见的tld相关不良反应为体重增加(47.5%，n = 85)、头痛(44.7%，n = 80)、失眠(39.7%，n = 71)、烦躁不安(36.9%，n = 66)、头晕(29.6%，n = 53)、脑雾(27.9%，n = 50)、神经紧张(27.4%，n = 49)、皮肤皮疹(24.6%，n = 44)和注意力不集中(21.2%，n = 38)。结论:约七分之一的患者报告了TLD的不良反应。用药错误率低，可能是由于有效的质量控制措施和稳定的患者参与了该方案。了解不良反应和用药错误的频率对于加强CCMDD规划至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Southern African Journal of Hiv Medicine 医学-病毒学

CiteScore

2.80

自引率

11.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.